Companies /Healthcare

Mineralys Therapeutics Inc

NASDAQ: MLYS Biotechnology
$14.80
▼ $0.53 (−3.46%) today
Markets open · 1:44pm ET

MLYS at a Glance

Valuation
Market cap
$1.4B
Profitability
EPS (TTM)
$-4.30
Price
52-week range
$15 – $45
Street target
$43.56

Headquartered in Radnor, PA Fiscal year ends December NASDAQ: MLYS mineralystx.com

About Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing medicines for hypertension and aldosterone-related adverse outcomes in comorbid conditions. These include chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its sole product candidate, lorundrostat, is an investigational, orally administered, highly selective aldosterone synthase (CYP11B2) inhibitor. It has 374-fold in vitro selectivity over cortisol synthase and an observed half-life of 10–12 hours. The company has completed six late-stage clinical trials of lorundrostat, including the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. Its NDA for uncontrolled and resistant hypertension is under FDA review, with a PDUFA target date of December 22, 2026. The company currently generates no revenue and is building a commercial infrastructure, including a sales force, medical affairs team, brand marketing and a patient support program, ahead of a potential U.S. launch. It funds operations with cash, investments and a senior secured term loan entered into in June 2026. Mineralys was founded by Catalys Pacific. Updated

MLYS Coverage

Frequently Asked Questions

What does Mineralys Therapeutics do?

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing medicines for hypertension and aldosterone-related adverse outcomes in comorbid conditions. These include chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone.

What is the MLYS stock price target?

The Wall Street consensus 12-month price target for MLYS is $43.56.